Ala-Glu-Asp-Gly. The pineal tetrapeptide behind 30+ years of Russian telomerase and longevity research — now with independent Western replication.
Epithalon (also spelled Epitalon, and referred to as AEDG after its amino acid code) is a synthetic tetrapeptide — just four amino acids, Ala-Glu-Asp-Gly — developed by Russian scientist Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, starting in the 1980s. It's a synthetic analog of the active component within epithalamin, a polypeptide extract originally isolated from bovine pineal glands.
Epithalon is arguably the flagship compound of an entire Russian research tradition — the "Khavinson bioregulators" — with over 30 years of clinical use in Russian geriatric practice behind it. That's a genuinely long track record, but it comes with an important caveat that deserves stating plainly rather than glossing over: the large-scale human data (a widely cited dataset covering 266 elderly patients, showing 1.6–4.1× fewer deaths over 6–8 years) comes from a single Russian research group, was not blinded or randomized, and has never been independently reproduced at Western clinical trial standards. It's a real, substantial dataset — just not one that's been replicated outside the lab that generated it.
The one piece of genuinely independent validation: a 2025 study by Al-Dulaimi and colleagues, published in Biogerontology, confirmed — in a Western lab, outside Khavinson's own group — that Epithalon extends telomere length in human cell lines via telomerase upregulation or ALT pathway activity. That's a meaningful development: the central telomere claim, first made by Khavinson's lab decades ago, has now been reproduced independently.
Epithalon's proposed mechanism has two main strands — one gets far more attention than the other, but both are part of the original research thesis.
Epithalon's evidence spans a wide range — from decades-old Russian animal work to a modern 2025 diabetic retinopathy cell study — worth breaking down by what's actually been shown where.
Epithalon's own research program has a real, historically documented pairing — but it's worth being upfront that the compound involved isn't currently in this catalog. Here's the honest picture, plus what's practically available today.
Worth knowing even though we don't currently stock it: Khavinson's own clinical program consistently shows Epithalon's largest benefits when combined with Thymalin, a separate thymic bioregulator peptide targeting immune function. This is a genuine research-documented combination, not a generic suggestion — but Thymalin is a distinct molecule from anything currently in the Paradise Peptides catalog, so it's mentioned here as context rather than a stack we can currently supply.
The practical pairing available in this catalog today: NAD+ is the coenzyme mitochondria and cells need for energy metabolism and DNA repair machinery, while Epithalon's research focus is telomere maintenance and pineal/circadian regulation. Both sit in the broader cellular-aging research space, addressing different layers of the aging process — genomic stability and circadian signalling from Epithalon, energy metabolism and repair capacity from NAD+ — rather than the same mechanism twice. Worth being clear that this is a complementary research-area pairing rather than a demonstrated pharmacological synergy the way GHRH + GHRP stacks are.
Another reasonable pairing within the catalog: MOTS-c targets mitochondrial energy signalling, Epithalon targets telomere/pineal biology — two different hallmarks-of-aging angles studied alongside each other in the broader longevity research community, though not a combination with dedicated joint trial data of its own.
The large Khavinson mortality dataset (266 patients) is real but single-lab, non-blinded, and non-randomized — presented here as context, not as confirmatory clinical evidence.